GSK PLC (GSK)
Industry Drug Manufacturers - General
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell
1,980.00p
Buy
1,981.00p
21.50p (+1.10%)
Prices updated at 12 Jun 2026, 16:35 BST
| Prices minimum 15 mins delay
Prices in GBX
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and im ...
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Drug Manufacturers - General
Chairman
Sir Jonathan Richard Symonds CBE
CEO
Mr. Luke Miels
Most recent earnings
31 Dec 2025
Fiscal year end
31 Dec 2025
Employees
66,841
Head office
79 New Oxford Street
London
United Kingdom
WC1A 1DG
Key personnel
Owner name | Salary |
|---|---|
Mr. Charles A. Bancroft Non-Executive Director, Senior Independent Director | - |
Sir Jonathan Richard Symonds CBE Non-Executive Director, Chairman | - |
Dr. Hal V Barron Non-Executive Director | - |
Ms. Wendy Becker Non-Executive Director | - |
Dr. Vishal Sikka Non-Executive Director | - |
Ms. Elizabeth McKee Anderson Non-Executive Director | - |
Dr. Anne Beal, M.D.,M.P.H. Non-Executive Director | - |
Dr. Harry C Dietz Non-Executive Director | - |
Dr. Jeannie Lee Non-Executive Director | - |
Dr. Gavin Screaton Non-Executive Director | - |
Ms. Julie Brown Executive Director, Chief Financial Officer | - |
Mr. Luke Miels Executive Director, Chief Executive Officer | - |
Mrs. Victoria Anne Whyte Company Secretary | - |
Top 5 shareholders
Owner name | No. of shares |
|---|---|
| Vanguard | 114,874,815 |
| Fidelity Management & Research Company LLC | 103,646,291 |
| Dodge & Cox | 92,207,640 |
| BlackRock Fund Advisors | 84,869,080 |
| Dodge & Cox International Stock Fund | 74,007,220 |
Director dealings
Date | Action |
|---|---|
| 15 May 2026 | Purchase |
| 15 May 2026 | Purchase |
| 12 May 2026 | Transfer in |
| 12 May 2026 | Purchase |
| 29 Apr 2026 | Purchase |
| 27 Apr 2026 | Transfer in |
| 14 Apr 2026 | D |
| 14 Apr 2026 | D |
| 14 Apr 2026 | D |
| 14 Apr 2026 | D |
| 14 Apr 2026 | D |
| 14 Apr 2026 | D |
| 13 Apr 2026 | Transfer in |
| 13 Apr 2026 | Purchase |
| 09 Apr 2026 | Purchase |
| 09 Apr 2026 | Purchase |
| 09 Apr 2026 | Purchase |
| 09 Apr 2026 | D |
| 09 Apr 2026 | D |
| 09 Apr 2026 | Purchase |
Please note that past performance is not a reliable indicator of future returns.